Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D6H9TE
|
|||
| Drug Name |
SEA-CD70
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 1 | [1] | |
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1 | [1] | ||
| Company |
Seagen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CD70 antigen (CD27-L) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| TNFalpha Signaling Pathway | ||||
| RANKL Signaling Pathway | ||||
| Reactome | TNFs bind their physiological receptors | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04227847) A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Seagen. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.